C_1-C_6 alkylcarbonyloxy, C_1-C_6 alkoxycarbonyl, amino (-NH_2), -$CON(R^6)_2$, C_1-C_6 alkylamino, di-(C_1-C_6 alkyl)amino, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkyloxy, C_3-C_6 cycloalkylmethyl, -$[O]_p$-$(CH_2)_q$-O-R^7 and a 4- to 6-membered saturated or unsaturated heterocyclic ring (optionally substituted with at least one substituent selected from C_1-C_4 alkyl and C_1-C_4 alkoxy);

each R^6 independently represents a hydrogen atom or a C_1-C_6 alkyl group;


p is 0 or 1;

q is 1, 2, 3 or 4; and

R^7 represents a C_1-C_6 alkyl group;

for use in the prevention or treatment of an ataxic disorder, in particular a spinocerebellar ataxic disorder.

In one aspect of the present disclosure, there is provided a use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of an ataxic disorder,




(I)

wherein

R^1 represents a hydrogen or fluorine atom or a trifluoromethyl group;

R^2 represents a group –X-Y-R^3;

X and Y each independently represent a bond, an oxygen atom or a group -


C(O), -$S(O)_n$, -$C(O)NR^4$, -$S(O)_2NR^4$, -NR^4, , or -CR^4R^5-, provided that X and Y cannot both simultaneously represent a bond and

The present disclosure also provides a method of treating, or reducing the risk of, an ataxic disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.

The compounds of formula (I) and pharmaceutically acceptable salts thereof are known from WO 2013/027000, the entire contents of which are incorporated herein by reference.

CLAIMS

1. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of an ataxic disorder,





(I)

wherein

R^1 represents a hydrogen or fluorine atom or a trifluoromethyl group;

R^2 represents a group $-X-Y-R^3$;

X and Y each independently represent a bond, an oxygen atom or a group -C(O), $-S(O)_n$, $-C(O)NR^4$, $-S(O)_2NR^4$, $-NR^4$, ,  or $-CR^4R^5-$, provided that X and Y cannot both simultaneously represent a bond and provided that if X and Y are both other than a bond, then at least one of X and Y represents $-CR^4R^5-$;

n is 0, 1 or 2;

each R^4 independently represents a hydrogen atom or a C_1-C_6 alkyl or C_1-C_6 haloalkyl group;

each R^5 independently represents a hydrogen atom, a C_1-C_6 alkyl or C_1-C_6 haloalkyl group or =CH-;

R^3 represents a 3- to 10-membered saturated or unsaturated carbocyclic or heterocyclic ring system, the ring system itself being optionally substituted by at least one substituent selected from halogen, hydroxyl, cyano, oxo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkylthio, C_1-C_6 alkylsulphinyl, C_1-C_6 alkylsulphonyl, C_1-C_6 alkylcarbonyl,

C_1-C_6 alkylcarbonyloxy, C_1-C_6 alkoxycarbonyl, amino, -$CON(R^6)_2$, C_1-C_6 alkylamino, di-(C_1-C_6 alkyl)amino, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkyloxy, C_3-C_6 cycloalkylmethyl, -$[O]_p$-$(CH_2)_q$-O-R^7 and a 4- to 6-membered saturated or unsaturated heterocyclic ring (optionally substituted with at least one substituent selected from C_1-C_4 alkyl and C_1-C_4 alkoxy);

each R^6 independently represents a hydrogen atom or a C_1-C_6 alkyl group;

p is 0 or 1;

q is 1, 2, 3 or 4; and

R^7 represents a C_1-C_6 alkyl group.

2. Use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein the medicament is for the prevention or treatment of a spinocerebellar ataxic disorder or Friedreich's ataxia.

3. Use of a compound of Formula (I) according to claim 1 or claim 2, wherein the compound of Formula (I) is selected from

4-Hydroxy-6-(2-phenylethyl)pyridazin-3(2H)-one;

6-[2-(4-Fluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one;

4-Hydroxy-6-{2-[5-(trifluoromethyl)pyridin-2-yl]ethyl}pyridazin-3(2H)-one;

6-[(4-Chlorobenzyl)sulfanyl]-4-hydroxypyridazin-3(2H)-one;

4-Hydroxy-6-{2-[6-(trifluoromethyl)pyridin-3-yl]ethyl}pyridazin-3(2H)-one;

6-[2-(3-Fluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one;

6-[2-(2-Fluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one;

6-[2-(3,5-Difluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one;

6-[2-(3,4-Difluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one;

4-Hydroxy-6-{2-[3-(trifluoromethoxy)phenyl]ethyl}pyridazin-3(2H)-one;

4-Hydroxy-6-{2-[3-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one;

4-Hydroxy-6-{2-[5-(trifluoromethyl)pyridin-3-yl]ethyl}pyridazin-3(2H)-one;

6-(2-Cyclohexylethyl)-4-hydroxypyridazin-3(2H)-one;

6-(2-Cyclopropylethyl)-4-hydroxypyridazin-3(2H)-one;

6-(2-Cyclopentylethyl)-4-hydroxypyridazin-3(2H)-one;

4-Hydroxy-6-[2-(4-methoxycyclohexyl)ethyl]pyridazin-3(2H)-one;

6-(3-Methylbenzyl)-4-hydroxypyridazin-3(2H)-one;
4-Hydroxy-6-(3-(trifluoromethyl)benzyl)pyridazin-3(2H)-one;
4-Hydroxy-6-[2-(oxan-4-yl)ethyl]pyridazin-3(2H)-one;
6-{[(4-Fluorophenyl)methyl](methyl)amino}-4-hydroxy-pyridazin-3(2H)-one;
6-[2-(2,6-Difluorophenyl)ethyl]-4-hydroxy-pyridazin-3(2H)-one;
6-[2-(2-Chloro-6-fluorophenyl)ethyl]-4-hydroxy-pyridazin-3(2H)-one;
6-{[3,5-bis(Trifluoromethyl)phenyl]methyl}-4-hydroxypyridazin-3(2H)-one;
6-(1-Phenylethyl)-4-hydroxypyridazin-3(2H)-one;
6-(Cyclopropylmethyl)-4-hydroxy-2,3-dihydropyridazin-3-one;
4-Hydroxy-6-{1-[4-(trifluoromethyl)phenyl]cyclopropyl}-2,3-dihydropyridazin-3-one;
6-{2-[2-Chloro-4-(trifluoromethyl)phenyl]ethyl}-4-hydroxy-2,3-dihydropyridazin-3-one;
6-{2-[2-Fluoro-4-(trifluoromethyl)phenyl]ethyl}-4-hydroxy-2,3-dihydropyridazin-3-one;
6-{2-[3,5-bis(Trifluoromethyl)phenyl]ethyl}-4-hydroxy-2,3-dihydropyridazin-3-one;
6-{2-[2,4-bis(Trifluoromethyl)phenyl]ethyl}-4-hydroxy-2,3-dihydro-pyridazin-3-one;
6-{2-[3,4-bis(Trifluoromethyl)phenyl]ethyl}-4-hydroxy-2,3-dihydropyridazin-3-one;
4-Hydroxy-6-(3-methyl-4-(trifluoromethyl)phenethyl)pyridazin-3(2H)-one;
3,4-bis(Benzyloxy)-6-((3-chloro-4-(trifluoromethyl)phenyl)ethyl)-pyridazine;
4-Hydroxy-6-{2-[2-methyl-4-(trifluoromethyl)phenyl]ethyl}-2,3-dihydropyridazin-3-one;
6-{2-[3,5-Difluoro-4-(trifluoromethyl)phenyl]ethyl}-4-hydroxy-2,3-dihydropyridazin-3-one;
6-{2-[3-Fluoro-4-(trifluoromethyl)phenyl]ethyl}-4-hydroxy-2,3-dihydropyridazin-3-one;
and pharmaceutically acceptable salts thereof.

4. Use of a compound of formula (I) according to any one of claims 1 to 3, wherein the compound of formula (I) is
6-[2-(4-Fluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one or a pharmaceutially acceptable salt thereof.

5. Use of a compound of formula (I) according to any one of claims 1 to 3, wherein the compound of formula (I) is 4-Hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one or a pharmaceutially acceptable salt thereof.

6. Use of a compound of formula (I) according to any one of claims 1 to 3, wherein the compound of formula (I) is 6-(4-Chlorobenzyl)-4-hydroxypyridazin-3(2H)-one or a pharmaceutially acceptable salt thereof.

7. Use of a compound of formula (I) according to any one of claims 1 to 3, wherein the compound of formula (I) is
6-(2-Fluorobenzyl)-4-hydroxypyridazin-3(2H)-one or a pharmaceutially acceptable salt thereof.

8. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any preceding claim, wherein the medicament is for reducing the risk of an ataxic disorder.

9. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein the medicament is for the reduction of symptoms associated with an ataxic disorder.

10. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 9, wherein the medicament is for improving gait, balance, limb coordination and/or speech.

11. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein the medicament is for increasing the period of time between episodes of the ataxic disorder.

12. Use of a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in any of claims 1 to 7 in association with a pharmaceutically acceptable adjuvant, diluent or carrier, in the manufacture of a medicament for the prevention or treatment of an ataxic disorder.

13. Use according to claim 12, wherein the pharmaceutical composition further comprises D-serine, D-serine ethyl ester, D-cycloserine, amantadine, amantadine hydrochloride, buspirone, acetazolamide, topiramate, divalproex sodium, L-dopa, propranolol, primidone, clonazepam, levetiracetam, carbamazepine, gabapentin, baclofen, ondansetron, tizanidine or pramipexole.

14. Use of a pharmaceutical composition according to claim 12 or claim 13, wherein the medicament is for the prevention or treatment of a spinocerebellar ataxic disorder or Friedreich's ataxia.

15. Use of a pharmaceutical composition according to claim 12 or claim 13, wherein the medicament is for reducing the risk of an ataxic disorder.

16. Use of a pharmaceutical composition according to claim 12 or claim 13, wherein the medicament is for the reduction of the symptoms associated with an ataxic disorder.

17. Use of a pharmaceutical composition according to claim 16, wherein the medicament is for improving gait, balance, limb coordination and/or speech.

18. Use of a pharmaceutical composition according to claim 12 or claim 13, wherein the medicament is for increasing the period of time between episodes of the ataxic disorder.